These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 29040662)

  • 21. Molecular classification of patients with grade II/III glioma using quantitative MRI characteristics.
    Bahrami N; Hartman SJ; Chang YH; Delfanti R; White NS; Karunamuni R; Seibert TM; Dale AM; Hattangadi-Gluth JA; Piccioni D; Farid N; McDonald CR
    J Neurooncol; 2018 Sep; 139(3):633-642. PubMed ID: 29860714
    [TBL] [Abstract][Full Text] [Related]  

  • 22. HIP1R and vimentin immunohistochemistry predict 1p/19q status in IDH-mutant glioma.
    Felix M; Friedel D; Jayavelu AK; Filipski K; Reinhardt A; Warnken U; Stichel D; Schrimpf D; Korshunov A; Wang Y; Kessler T; Etminan N; Unterberg A; Herold-Mende C; Heikaus L; Sahm F; Wick W; Harter PN; von Deimling A; Reuss DE
    Neuro Oncol; 2022 Dec; 24(12):2121-2132. PubMed ID: 35511748
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Analysis of IDH mutation, 1p/19q deletion, and PTEN loss delineates prognosis in clinical low-grade diffuse gliomas.
    Sabha N; Knobbe CB; Maganti M; Al Omar S; Bernstein M; Cairns R; Çako B; von Deimling A; Capper D; Mak TW; Kiehl TR; Carvalho P; Garrett E; Perry A; Zadeh G; Guha A; Sidney Croul
    Neuro Oncol; 2014 Jul; 16(7):914-23. PubMed ID: 24470545
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Radiation and chemotherapy for high-risk lower grade gliomas: Choosing between temozolomide and PCV.
    McDuff SGR; Dietrich J; Atkins KM; Oh KS; Loeffler JS; Shih HA
    Cancer Med; 2020 Jan; 9(1):3-11. PubMed ID: 31701682
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neuroimaging-Based Classification Algorithm for Predicting 1p/19q-Codeletion Status in
    Batchala PP; Muttikkal TJE; Donahue JH; Patrie JT; Schiff D; Fadul CE; Mrachek EK; Lopes MB; Jain R; Patel SH
    AJNR Am J Neuroradiol; 2019 Mar; 40(3):426-432. PubMed ID: 30705071
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical management and survival outcomes of patients with different molecular subtypes of diffuse gliomas in China (2011-2017): a multicenter retrospective study from CGGA.
    Zhang K; Liu X; Li G; Chang X; Li S; Chen J; Zhao Z; Wang J; Jiang T; Chai R
    Cancer Biol Med; 2022 Nov; 19(10):1460-76. PubMed ID: 36350010
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Significance of IDH mutations varies with tumor histology, grade, and genetics in Japanese glioma patients.
    Mukasa A; Takayanagi S; Saito K; Shibahara J; Tabei Y; Furuya K; Ide T; Narita Y; Nishikawa R; Ueki K; Saito N
    Cancer Sci; 2012 Mar; 103(3):587-92. PubMed ID: 22136423
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Advanced imaging parameters improve the prediction of diffuse lower-grade gliomas subtype, IDH mutant with no 1p19q codeletion: added value to the T2/FLAIR mismatch sign.
    Lee MK; Park JE; Jo Y; Park SY; Kim SJ; Kim HS
    Eur Radiol; 2020 Feb; 30(2):844-854. PubMed ID: 31446467
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A PRDX1-p38α heterodimer amplifies MET-driven invasion of IDH-wildtype and IDH-mutant gliomas.
    Wirthschaft P; Bode J; Simon AEM; Hoffmann E; van Laack R; Krüwel T; Dietrich F; Bucher D; Hahn A; Sahm F; Breckwoldt MO; Kurz FT; Hielscher T; Fischer B; Dross N; Ruiz de Almodovar C; von Deimling A; Herold-Mende C; Plass C; Boulant S; Wiestler B; Reifenberger G; Lichter P; Wick W; Tews B
    Int J Cancer; 2018 Sep; 143(5):1176-1187. PubMed ID: 29582423
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Static
    Song S; Wang L; Yang H; Shan Y; Cheng Y; Xu L; Dong C; Zhao G; Lu J
    Eur Radiol; 2021 Jun; 31(6):4087-4096. PubMed ID: 33211141
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Low FoxG1 and high Olig-2 labelling indices define a prognostically favourable subset in isocitrate dehydrogenase (IDH)-mutant gliomas.
    Schäfer S; Behling F; Skardelly M; Koch M; Ott I; Paulsen F; Tabatabai G; Schittenhelm J
    Neuropathol Appl Neurobiol; 2018 Feb; 44(2):207-223. PubMed ID: 29053887
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Machine learning modeling of genome-wide copy number alteration signatures reliably predicts IDH mutational status in adult diffuse glioma.
    Nuechterlein N; Shapiro LG; Holland EC; Cimino PJ
    Acta Neuropathol Commun; 2021 Dec; 9(1):191. PubMed ID: 34863298
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas.
    Akyerli CB; Yüksel Ş; Can Ö; Erson-Omay EZ; Oktay Y; Coşgun E; Ülgen E; Erdemgil Y; Sav A; von Deimling A; Günel M; Yakıcıer MC; Pamir MN; Özduman K
    J Neurosurg; 2018 Apr; 128(4):1102-1114. PubMed ID: 28621624
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors.
    Eckel-Passow JE; Lachance DH; Molinaro AM; Walsh KM; Decker PA; Sicotte H; Pekmezci M; Rice T; Kosel ML; Smirnov IV; Sarkar G; Caron AA; Kollmeyer TM; Praska CE; Chada AR; Halder C; Hansen HM; McCoy LS; Bracci PM; Marshall R; Zheng S; Reis GF; Pico AR; O'Neill BP; Buckner JC; Giannini C; Huse JT; Perry A; Tihan T; Berger MS; Chang SM; Prados MD; Wiemels J; Wiencke JK; Wrensch MR; Jenkins RB
    N Engl J Med; 2015 Jun; 372(26):2499-508. PubMed ID: 26061753
    [TBL] [Abstract][Full Text] [Related]  

  • 35. DNA copy number analysis of Grade II-III and Grade IV gliomas reveals differences in molecular ontogeny including chromothripsis associated with IDH mutation status.
    Cohen A; Sato M; Aldape K; Mason CC; Alfaro-Munoz K; Heathcock L; South ST; Abegglen LM; Schiffman JD; Colman H
    Acta Neuropathol Commun; 2015 Jun; 3():34. PubMed ID: 26091668
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association between altered metabolism and genetic mutations in human glioma.
    Pearl H; Fleischer CC
    Cancer Rep (Hoboken); 2023 May; 6(5):e1799. PubMed ID: 36916606
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molecular classification of adult diffuse gliomas: conflicting IDH1/IDH2, ATRX, and 1p/19q results.
    Ballester LY; Huse JT; Tang G; Fuller GN
    Hum Pathol; 2017 Nov; 69():15-22. PubMed ID: 28549927
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Extent of Surgical Resection in Lower-Grade Gliomas: Differential Impact Based on Molecular Subtype.
    Patel SH; Bansal AG; Young EB; Batchala PP; Patrie JT; Lopes MB; Jain R; Fadul CE; Schiff D
    AJNR Am J Neuroradiol; 2019 Jul; 40(7):1149-1155. PubMed ID: 31248860
    [TBL] [Abstract][Full Text] [Related]  

  • 39. IDH mutation status trumps the Pignatti risk score as a prognostic marker in low-grade gliomas.
    Etxaniz O; Carrato C; de Aguirre I; Queralt C; Muñoz A; Ramirez JL; Rosell R; Villà S; Diaz R; Estival A; Teixidor P; Indacochea A; Ahjal S; Vilà L; Balañá C
    J Neurooncol; 2017 Nov; 135(2):273-284. PubMed ID: 28884377
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Molecular Subtype Classification in Lower-Grade Glioma with Accelerated DTI.
    Aliotta E; Nourzadeh H; Batchala PP; Schiff D; Lopes MB; Druzgal JT; Mukherjee S; Patel SH
    AJNR Am J Neuroradiol; 2019 Sep; 40(9):1458-1463. PubMed ID: 31413006
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.